Liver transplantation for hepatocellular carcinoma: An update

Jean F. Botha, Alan Norman Langnas

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95% of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)762-767
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number8
DOIs
StatePublished - Sep 2006

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Transplantation
Donor Selection
Neoplasms
Living Donors
Therapeutics
Liver Cirrhosis
Patient Selection
Carcinoma
Liver

Keywords

  • Adjuvant therapy
  • Hepatocellular carcinoma
  • Liver transplantation
  • Living donors

ASJC Scopus subject areas

  • Oncology

Cite this

Liver transplantation for hepatocellular carcinoma : An update. / Botha, Jean F.; Langnas, Alan Norman.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 8, 09.2006, p. 762-767.

Research output: Contribution to journalArticle

@article{138bb6af0c954761937e8ba31ffa3e1e,
title = "Liver transplantation for hepatocellular carcinoma: An update",
abstract = "Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95{\%} of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.",
keywords = "Adjuvant therapy, Hepatocellular carcinoma, Liver transplantation, Living donors",
author = "Botha, {Jean F.} and Langnas, {Alan Norman}",
year = "2006",
month = "9",
doi = "10.6004/jnccn.2006.0066",
language = "English (US)",
volume = "4",
pages = "762--767",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Liver transplantation for hepatocellular carcinoma

T2 - An update

AU - Botha, Jean F.

AU - Langnas, Alan Norman

PY - 2006/9

Y1 - 2006/9

N2 - Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95% of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.

AB - Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95% of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.

KW - Adjuvant therapy

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Living donors

UR - http://www.scopus.com/inward/record.url?scp=33748803594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748803594&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0066

DO - 10.6004/jnccn.2006.0066

M3 - Article

C2 - 16948954

AN - SCOPUS:33748803594

VL - 4

SP - 762

EP - 767

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 8

ER -